🇺🇸 FDA
Patent

US 11944644

T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof

granted A61KA61K2039/505A61K2039/804

Quick answer

US patent 11944644 (T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof) held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
Grant date
Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/804, A61K2239/28, A61K2239/31